SPP - Extension of Closing Date
15 August 2023
ASX Code: MXC
LSE Code: MXC
MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) refers to its prospectus lodged with ASIC and released on the ASX on 3 August 2023 in relation to its security purchase plan (SPP), as first announced to the ASX on 1 August 2023 (Prospectus).
Defined terms used in this announcement have the meaning given to them in the Prospectus, unless specified otherwise.
The Company wishes to advise that the Closing Date for the SPP has been extended from 5:00pm (AWST) on Friday, 18 August 2023 until 5:00pm (AWST) on Friday, 25 August 2023. The Company has also released an updated Appendix 3B reflecting the extended Closing Date.
The SPP timetable has been revised as follows:
| Action | Date |
| Record Date for SPP | 5:00pm (AWST) on 31 July 2023 |
| Announcement of SPP and lodgment of Appendix 3B with ASX | 1 August 2023 |
| Lodgment of Prospectus for issue of SPP Securities with ASIC and ASX | 3 August 2023 |
| Opening date of the SPP Offer under the Prospectus | 4 August 2023 |
| Closing Date of the SPP Offer under the Prospectus** | 25 August 2023 |
| Announcement of the results of the SPP | 29 August 2023 |
| Issue of SPP Shares and lodgement of Appendix 2A for the SPP Shares with ASX | 1 September 2023 |
| General Meeting to approve the issuance of the SPP Options | 5 September 2023 |
| Issue of SPP Options and lodgement of forms for the SPP Options with ASX | 6 September 2023 |
\* The above dates are indicative only and may change without prior notice.
**Subscribers under the SPP Offer should ensure that they have lodged their SPP Application Form by this date.
Further details of the SPP Offer, including details on how to apply under the SPP Offer and key risks associated with an investment in the Company are set out in the Prospectus. Applications for new Shares and free attaching Options (subject to Shareholder approval at the upcoming general meeting) under the SPP Offer may only be made by completing the Application Form accompanying the Prospectus in accordance with the instructions outlined on the Application Form. Shareholders eligible to participate in the SPP Offer should read the Prospectus carefully and consult their professional advisers as necessary.
-Ends-
Authorised for release by the board of directors, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6555 2950 | MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6555 2950 |
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
LinkedIn: MGC Pharmaceuticals Ltd.
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.